Renaissance Technologies’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-91,173
| Closed | -$3.09M | – | 3605 |
|
|
2025
Q4 | $3.09M | Buy |
91,173
+56,862
| +166% | +$1.77M | ﹤0.01% | 1618 |
|
|
2025
Q3 | $885K | Sell |
34,311
-28,162
| -45% | -$369K | ﹤0.01% | 2549 |
|
|
2025
Q2 | $500K | Sell |
62,473
-18,630
| -23% | -$142K | ﹤0.01% | 2831 |
|
|
2025
Q1 | $792K | Buy |
81,103
+34,886
| +75% | +$343K | ﹤0.01% | 2545 |
|
|
2024
Q4 | $584K | Buy |
46,217
+9,392
| +26% | +$119K | ﹤0.01% | 2773 |
|
|
2024
Q3 | $592K | Buy |
36,825
+11,337
| +44% | +$229K | ﹤0.01% | 2705 |
|
|
2024
Q2 | $622K | Buy |
25,488
+13,238
| +108% | +$611K | ﹤0.01% | 2595 |
|
|
2024
Q1 | $880K | Buy |
+12,250
| New | +$1.7M | ﹤0.01% | 2564 |
|
|
2023
Q3 | – | Sell |
-6,413
| Closed | -$959K | – | 4024 |
|
|
2023
Q2 | $959K | Sell |
6,413
-7,150
| -53% | -$1.11M | ﹤0.01% | 2489 |
|
|
2023
Q1 | $1.99M | Buy |
13,563
+9,525
| +236% | +$1.93M | ﹤0.01% | 2034 |
|
|
2022
Q4 | $640K | Buy |
4,038
+325
| +9% | +$52K | ﹤0.01% | 2798 |
|
|
2022
Q3 | $715K | Buy |
+3,713
| New | +$702K | ﹤0.01% | 2703 |
|
|
2022
Q2 | – | Sell |
-5,688
| Closed | -$1M | – | 4507 |
|
|
2022
Q1 | $1M | Buy |
5,688
+3,325
| +141% | +$628K | ﹤0.01% | 2727 |
|
|
2021
Q4 | $694K | Sell |
2,363
-2,412
| -51% | -$645K | ﹤0.01% | 2917 |
|
|
2021
Q3 | $1.19M | Buy |
+4,775
| New | +$1.26M | ﹤0.01% | 2455 |
|
|
2021
Q1 | – | Sell |
-1,388
| Closed | -$219K | – | 3630 |
|
|
2020
Q4 | $219K | Buy |
+1,388
| New | +$302K | ﹤0.01% | 3107 |
|
Renaissance Technologies's RAPT Position: Q1 2026 in Review
Renaissance Technologies sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 91,173 shares — an estimated $3.09M sold.
Renaissance Technologies first reported a position in RAPT in Q4 2020 and held it in 16 quarters. The position peaked at $3.09M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Renaissance Technologies reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Renaissance Technologies sold 91,173 RAPT Therapeutics shares in Q1 2026, an estimated $3.09M.
- Renaissance Technologies first reported a position in RAPT Therapeutics in Q4 2020 and held it in 16 quarters.
- Renaissance Technologies's RAPT Therapeutics position peaked at $3.09M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.